News

EN311 by Eneapharm at ESPGHAN 2025

EN311 by Eneapharm at ESPGHAN 2025

Apr 10, 2025

We’re proud to be taking part in ESPGHAN 2025, the leading European event dedicated to

Read more
EN311: a true therapeutic breakthrough for EPI

EN311: a true therapeutic breakthrough for EPI

Jan 12, 2025

But first… what is EPI? Exocrine Pancreatic Insufficiency (EPI) is a chronic condition in which

Read more
Eneapharm publishes new results in a leading scientific journal

Eneapharm publishes new results in a leading scientific journal

Nov 8, 2024

We are very happy to announce the release of our latest study in the European

Read more
Eneapharm : Winner of the 2019 i-Lab Competition

Eneapharm : Winner of the 2019 i-Lab Competition

Jul 4, 2019

We are proud and honored to have been awarded the prestigious i-Lab Innovation Prize, organized

Read more
Eneapharm signs a collaboration agreement with Crealia, the seed fund of the Occitanie Region, and strengthens its equity capital

Eneapharm signs a collaboration agreement with Crealia, the seed fund of the Occitanie Region, and strengthens its equity capital

Nov 22, 2018

We are proud to announce the signing of a strategic partnership with Crealia, a key

Read more
Eneapharm joins the Nubbo incubation program

Eneapharm joins the Nubbo incubation program

Nov 22, 2018

We’re excited to join Nubbo, a leading incubator supporting high-impact technological and societal innovations. This

Read more